» Articles » PMID: 10978049

Impact of White Matter Changes on Clinical Manifestation of Alzheimer's Disease: A Quantitative Study

Overview
Journal Stroke
Date 2000 Sep 8
PMID 10978049
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: There have been conflicting results involving the clinical significance of white matter changes in patients with Alzheimer's disease (AD). We studied the association between the volume of white matter hyperintensities (WMHs) on T2-weighted images and cognitive, neurological, and neuropsychiatric symptoms.

Methods: The subjects were 76 AD patients who had WMHs but no obvious cerebrovascular diseases. We quantified the volume of WMHs by using fast-fluid-attenuated inversion recovery images and whole brain atrophy by using 3D spoiled gradient-echo images. Effects of WMHs and brain atrophy on dementia severity, cognitive function, neuropsychiatric disturbances, and neurological findings were examined.

Results: Whole brain atrophy was significantly associated with dementia severity and cognitive disturbances, as well as with grasp reflex and some kinds of neuropsychiatric disturbances. After we controlled for the effects of brain atrophy, duration of symptoms, and demographic factors, we found that WMH volume was not associated with global cognitive disturbances or dementia severity but was significantly associated with urinary incontinence, grasp reflex, and aberrant motor behaviors. Brain atrophy and WMH volume were not significantly correlated either before or after controlling for age, sex, education, and duration of symptoms. WMH volume was associated with hypertension, but brain atrophy was not positively correlated with any vascular risk factors.

Conclusions: Our results support the hypothesis that WMHs in AD patients are superimposed phenomena of vascular origin. WMHs contribute to specific neurological and neuropsychiatric manifestations but not to global cognitive impairment, which is more closely associated with brain atrophy.

Citing Articles

Older adults with reduced cerebrovascular reactivity exhibit high white matter hyperintensity burden.

Kapoor A, Dutt S, Alitin J, Sible I, Marshall A, Shenasa F Neurobiol Aging. 2024; 139:5-10.

PMID: 38579393 PMC: 11896757. DOI: 10.1016/j.neurobiolaging.2024.03.006.


Association Between Late-Life Neuropsychiatric Symptoms and Cognitive Decline in Relation to White Matter Hyperintensities and Amyloid Burden.

Chan C, Pettigrew C, Soldan A, Zhu Y, Wang M, Albert M J Alzheimers Dis. 2022; 86(3):1415-1426.

PMID: 35213370 PMC: 9969328. DOI: 10.3233/JAD-215267.


White matter microglia heterogeneity in the CNS.

Amor S, McNamara N, Gerrits E, Marzin M, Kooistra S, Miron V Acta Neuropathol. 2021; 143(2):125-141.

PMID: 34878590 DOI: 10.1007/s00401-021-02389-x.


White matter hyperintensity topography in Alzheimer's disease and links to cognition.

Garnier-Crussard A, Bougacha S, Wirth M, Dautricourt S, Sherif S, Landeau B Alzheimers Dement. 2021; 18(3):422-433.

PMID: 34322985 PMC: 9292254. DOI: 10.1002/alz.12410.


Protective effects of edaravone on white matter pathology in a novel mouse model of Alzheimer's disease with chronic cerebral hypoperfusion.

Feng T, Yamashita T, Sasaki R, Tadokoro K, Matsumoto N, Hishikawa N J Cereb Blood Flow Metab. 2020; 41(6):1437-1448.

PMID: 33106078 PMC: 8142121. DOI: 10.1177/0271678X20968927.